Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs
Investigational and unapproved. Findings below describe what trials and reports have observed. Nothing here is an endorsement, a claim of safety or effectiveness, or a clinical recommendation.

Enicepatide

INVESTIGATIONAL

GIP and GLP-1 receptor dual agonist

6
graded results
0
ongoing records
4
effect domains
Evidence spread
High evidence 0Moderate evidence 0Low evidence 4Very low evidence 2

Enicepatide is investigational in the scoped programme below. Study records do not establish approval, safety or personal suitability. Results describe observations and do not provide treatment advice.

Dated status sources

INVESTIGATIONAL Global programme; Obesity; Subcutaneous injection; as of 2026-07-13. ClinicalTrials.gov

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Enicepatide INVESTIGATIONAL
weight-loss Decrease
Low evidence

Phase 1 (4 once-weekly doses) produced dose-dependent weight loss by day 29 in overweight/obese participants.

Chakravarthy MV et al. Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP r... Source
PopulationPhase 1 double-blind RCT (NCT04838405), healthy participants with overweight/obesity; ~4 wk; placebo comparator
Fundingindustry - Roche
Comparatorsplacebo
Enicepatide INVESTIGATIONAL
weight-loss Decrease
Very low evidence

CT-388 (Roche/Genentech, ex-Carmot) is a once-weekly subcutaneous GLP-1/GIP dual agonist. In a phase 2 obesity trial it achieved a statistically significant...

Roche/Genentech phase 2 topline, Jan 2026; earlier phase 1b (Applied Clinical Trials) Source
Full findingCT-388 (Roche/Genentech, ex-Carmot) is a once-weekly subcutaneous GLP-1/GIP dual agonist. In a phase 2 obesity trial it achieved a statistically significant placebo-adjusted weight loss of 22.5% at 48 weeks at the highest dose (24 mg), without reaching a plateau; 87% of the 24 mg group achieved >=10% and 47.8% >=20% weight loss, and 54% reached BMI <30 (vs 13% placebo).
PopulationPhase 2: 469 adults with obesity or overweight + >=1 comorbidity, dose-escalation up to 24 mg once-weekly s.c., 48 weeks, randomised double-blind placebo-controlled
Fundingindustry - Roche (trial sponsor; inferred from registration trial)
Comparatorsplacebo
Enicepatide INVESTIGATIONAL
weight-loss Decrease
Very low evidence

Phase 2 topline: clinically meaningful, statistically significant placebo-adjusted weight loss at the highest dose at 48 weeks.

Roche/Genentech press release: Roche announces positive Phase II results for dual GLP-1/G... Source
PopulationCT388-103, N=469 adults with obesity/overweight + >=1 comorbidity; 48 wk; phase 2 double-blind placebo-controlled RCT
Fundingindustry - Roche (trial sponsor; inferred from registration trial)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Enicepatide INVESTIGATIONAL
glycaemic Decrease
Low evidence

Improved glycaemic parameters during fasting and oral glucose tolerance testing in phase 1; HbA1c reductions reported in a phase 1b T2D cohort (conference).

Chakravarthy MV et al. Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP r... Source
PopulationPhase 1 overweight/obese (NCT04838405); ADA abstract 763-P = 12-wk cohort adults with obesity + T2D
Fundingindustry - Roche
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Enicepatide INVESTIGATIONAL
pharmacology Not directional
Low evidence

Unimolecular peptide dual GLP-1R/GIPR agonist that is cAMP signal-biased at both receptors (minimal receptor internalisation vs native ligands); PK supports...

Chakravarthy MV et al. Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP r... Source
Full findingUnimolecular peptide dual GLP-1R/GIPR agonist that is cAMP signal-biased at both receptors (minimal receptor internalisation vs native ligands); PK supports once-weekly dosing.
PopulationCell assays, mice, monkeys, phase 1 humans
Fundingindustry - Roche
Comparatorsnative GLP-1/GIP ligands
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Enicepatide INVESTIGATIONAL
Stomach and gut Increase
Low evidence

Generally well tolerated; GI adverse events mostly mild-to-moderate, consistent with incretin class.

Chakravarthy MV et al. Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP r... Source
PopulationPhase 1 (NCT04838405) and phase 2 CT388-103 (N=469)
Fundingindustry - Roche
Comparatorsplacebo